Clinical Trials Logo

Pediatric HIV Infection clinical trials

View clinical trials related to Pediatric HIV Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05069688 Recruiting - Clinical trials for Tuberculosis Infection

Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

Start date: July 7, 2023
Phase: Phase 1
Study type: Interventional

Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children. Current WHO-recommended rifampicin dosages result in low concentrations in most children, and high-dose rifampicin may improve outcomes and shorten treatment duration. Yet the impact of high-dose rifampicin on dolutegravir exposures has not been examined in children. This study aims to evaluate the safety and pharmacokinetics of dolutegravir twice daily among HIV/TB coinfected children receiving standard-dose and high-dose rifampicin.

NCT ID: NCT05006170 Recruiting - Clinical trials for Pediatric HIV Infection

Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV

Start date: August 3, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate steady-state pharmacokinetics of DTG dispersible tablets in children with HIV infection weighing from 6 to below 20 kg and to determine the dose of DTG that achieves adult target PK parameter(trough concentration; AUC24h)